SG11202106306YA - Active ester derivatives of testosterone, compositions and uses thereof - Google Patents

Active ester derivatives of testosterone, compositions and uses thereof

Info

Publication number
SG11202106306YA
SG11202106306YA SG11202106306YA SG11202106306YA SG11202106306YA SG 11202106306Y A SG11202106306Y A SG 11202106306YA SG 11202106306Y A SG11202106306Y A SG 11202106306YA SG 11202106306Y A SG11202106306Y A SG 11202106306YA SG 11202106306Y A SG11202106306Y A SG 11202106306YA
Authority
SG
Singapore
Prior art keywords
testosterone
compositions
active ester
ester derivatives
derivatives
Prior art date
Application number
SG11202106306YA
Other languages
English (en)
Inventor
Nathan Bryson
Avinash Chander Sharma
Original Assignee
Acerus Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acerus Biopharma Inc filed Critical Acerus Biopharma Inc
Publication of SG11202106306YA publication Critical patent/SG11202106306YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
SG11202106306YA 2018-12-14 2019-12-12 Active ester derivatives of testosterone, compositions and uses thereof SG11202106306YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862779854P 2018-12-14 2018-12-14
PCT/CA2019/051793 WO2020118437A1 (fr) 2018-12-14 2019-12-12 Dérivés esters actifs de la testostérone, compositions et utilisations associées

Publications (1)

Publication Number Publication Date
SG11202106306YA true SG11202106306YA (en) 2021-07-29

Family

ID=71072219

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106306YA SG11202106306YA (en) 2018-12-14 2019-12-12 Active ester derivatives of testosterone, compositions and uses thereof

Country Status (15)

Country Link
US (1) US20200188412A1 (fr)
EP (1) EP3893885A4 (fr)
JP (1) JP2022517724A (fr)
KR (1) KR20210131305A (fr)
CN (1) CN113365635A (fr)
AU (1) AU2019396139A1 (fr)
BR (1) BR112021011525A2 (fr)
CA (1) CA3123301A1 (fr)
CO (1) CO2021008962A2 (fr)
EA (1) EA202191378A1 (fr)
IL (1) IL283964A (fr)
MX (1) MX2021007032A (fr)
SG (1) SG11202106306YA (fr)
WO (1) WO2020118437A1 (fr)
ZA (1) ZA202104050B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156103A1 (fr) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Stéroïdes neuroactifs, compositions, et leurs utilisations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
ES2258694T3 (es) * 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
US20100016267A1 (en) * 2004-03-15 2010-01-21 Felix Theeuwes Pharmaceutical compositions for administraton to a sinus
CN103705462B (zh) * 2010-04-12 2016-08-31 克劳拉斯医疗有限公司 口服睾酮酯制剂以及包含其的治疗睾酮缺乏症的方法
WO2012156820A1 (fr) * 2011-05-15 2012-11-22 Trimel Pharmaceuticals Corp. Formulations intranasales bio-adhésives de gel de testostérone et leur utilisation pour traiter l'hypogonadisme chez les hommes
US20150290217A1 (en) * 2012-11-21 2015-10-15 Trimel Biopharma Srl Male testosterone titration methods, male intranasal testosterone bio-adhesive gel formulations and use thereof for treating hypogonadism and trt
AU2014232911B2 (en) * 2013-03-15 2019-04-04 Tolmar, Inc. Methods of treating testosterone deficiency
EP3185872B1 (fr) * 2014-08-28 2021-03-31 Board of Regents, The University of Texas System Formulations de testostérone et méthodes de traitement associées
RS62224B1 (sr) * 2015-03-02 2021-09-30 Medlab Clinical U S Inc Transmukozalni i transdermalni sistemi dostave
WO2017151911A1 (fr) * 2016-03-02 2017-09-08 Board Of Regents, The University Of Texas System Formulations de testostérone et méthodes de traitement associées
TWI790204B (zh) * 2016-06-02 2023-01-21 加拿大商阿爾宙斯製藥有限公司 鼻用大麻素組成物

Also Published As

Publication number Publication date
ZA202104050B (en) 2022-04-28
EP3893885A4 (fr) 2022-09-07
CA3123301A1 (fr) 2020-06-18
BR112021011525A2 (pt) 2021-08-31
EA202191378A1 (ru) 2021-10-04
KR20210131305A (ko) 2021-11-02
MX2021007032A (es) 2021-10-22
WO2020118437A1 (fr) 2020-06-18
CN113365635A (zh) 2021-09-07
CO2021008962A2 (es) 2021-10-29
US20200188412A1 (en) 2020-06-18
JP2022517724A (ja) 2022-03-10
EP3893885A1 (fr) 2021-10-20
AU2019396139A1 (en) 2021-07-15
IL283964A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
PL3668937T3 (pl) Kompozycje i zastosowania Z-1-chloro-2,3,3,3-tetrafluoroprop-1-enu
EP3452597A4 (fr) Procédés et compositions d'agents biologiquement actifs
EP3595653A4 (fr) Compositions de plinabuline et leur utilisation
EP3947353A4 (fr) Compositions et associations pharmaceutiques comprenant des inhibiteurs du récepteur des androgènes et leurs utilisations
EP3704254A4 (fr) Compositions de cas12c et procédés d'utilisation
EP3576782A4 (fr) Compositions de produit de recombinaison-peptide et leurs méthodes d'utilisation
EP3710036A4 (fr) Compositions d'acide ascorbique stables et leurs procédés d'utilisation
EP3761972A4 (fr) Compositions bioréactives et leurs procédés d'utilisation
EP3691677A4 (fr) Compositions de conjugués saccharide-polypeptide et leurs procédés d'utilisation
EP3634426A4 (fr) Compositions pour le traitement d'une fibrose
IL283968A (en) Benzamides of pyrazole-amino-pyrimidine type substances and their use
EP3600372A4 (fr) Compositions de synthékine et procédés d'utilisation
EP3303366A4 (fr) Dérivés de dolastatine 10 et utilisations de ceux-ci
EP3573620A4 (fr) Compositions pour le traitement de l'hypertension
EP3568233A4 (fr) Compositions de tensioactifs du type gemini et du type oligomère
EP3580344A4 (fr) Compositions d'augmentation du ncv et procédés d'utilisation de ces dernières
EP3675632A4 (fr) Procédés et compositions pour la conservation de tissu
EP3624595A4 (fr) Compositions édulcorées de siaménoside i et leurs utilisations
EP3490584A4 (fr) Méthodes et compositions pharmaceutiques destinées au traitement du mélanome
IL283964A (en) History of testosterone active ester, preparations and their uses
EP3490530A4 (fr) Composition à libération lente de principes actifs
EP3813815A4 (fr) Compositions et procédés d'utilisation de dérivés d'acide itaconique
EP3710069A4 (fr) Compositions de fluorescéine et de bénoxinate
EP3672618A4 (fr) Compositions et méthodes d'administration d'agents pharmacologiques
EP3694517A4 (fr) Compositions et méthodes de traitement de la fibrose